ClinicalTrials.gg
CompletedNCT01751984Updated Apr 4, 2022Results posted

A Study of the Efficacy and Safety of ETC-1002 in Participants With Statin Intolerance

A Phase 2 interventional study of ETC-1002 and Placebo in Hypercholesterolemia, sponsored by Esperion Therapeutics, Inc.. Completed at 5 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-04-04.

Sponsored by Esperion Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing bempedoic acid in Hypercholesterolemia — 1 open to participants now, 1 under way, 1 of them phase 3. bempedoic acid · Hypercholesterolemia.

Enrollment
18th of 21
56 · median 126
Started
2012
with 1 other
Phase 2
10 of 21
none open now
Registered
1st of 21
by date
Lead sponsor
15 of 21
Esperion Therapeutics, Inc.

Among the 21 studies testing bempedoic acid in Hypercholesterolemia, this one is the 18th largest by enrollment, is one of 2 that started in 2012, is one of 10 in phase 2, and was the 1st registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 21 studies testing bempedoic acid in Hypercholesterolemia is open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About bempedoic acid

bempedoic acid: first FDA approval 2020 (NEXLETOL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing bempedoic acid in Hypercholesterolemia, or all of them as a file.
02

Study summary

This study will assess the Low-Density Lipoprotein-Cholesterol (LDL-C) lowering efficacy and safety of ETC-1002 versus placebo in participants with hypercholesterolemia and a history of statin intolerance.

03

Conditions studied

  • Hypercholesterolemia

Keywords

  • lipid-lowering drugs
  • statin intolerance
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • A history of statin intolerance that began during statin treatment and resolved within 4 weeks of stopping the statin treatment
  • For participants on current lipid-regulating drugs - LDL-C 100-220 milligrams per deciliter (mg/dL) and triglycerides \<350 mg/dL (prior to wash-out of all lipid-regulating drugs and supplements)
  • For participants not on current lipid-regulating drugs - LDL-C 115-270 mg/dL and fasting TG \<400 mg/dL

Key Exclusion Criteria:

  • Acute significant cardiovascular disease
  • Poorly controlled hypertension
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    ETC-1002

    ETC-1002 treatment, once daily oral

    Drug: ETC-1002

  • Placebo comparator
    Placebo

    Placebo treatment, once daily oral

    Drug: Placebo

Interventions

  • Weeks 1-2, 60 milligrams per day (mg/day); Weeks 3-4, 120 mg/day; Weeks 5-6, 180 mg/day; Weeks 7-8, 240 mg/day

  • DrugPlacebo

    Placebo once daily for 8 weeks

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline to Week 8 in Calculated Low-Density Lipoprotein-Cholesterol (LDL-C)

    Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. Least square (LS) mean percent change from Baseline to Week 8 was based on an analysis of covariance (ANCOVA) model with effects of treatment and Baseline value as a covariate. Missing LDL-C values at Week 8 were imputed using the last observation carried forward (LOCF) procedure (only post-Baseline values were carried forward). A negative percent change from Baseline reflects clinical improvement.

    Time frame: Baseline; 8 weeks

Secondary outcomes

  1. Percent Change From Baseline to Weeks 2, 4, 6, and 8 in Calculated LDL-C

    Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. LS mean percent change from Baseline was based on an ANCOVA model with effects of treatment and Baseline value as a covariate. A negative percent change from Baseline reflects clinical improvement.

    Time frame: Baseline; Weeks 2, 4, 6, and 8

  2. Percent Change From Baseline to Week 8 in High-Density Lipoprotein-Cholesterol (HDL-C)

    Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. LS mean percent change from Baseline to Week 8 was based on an ANCOVA model with effects of treatment and Baseline value as a covariate. Missing values at Week 8 were imputed using the LOCF procedure (only post-Baseline values were carried forward). A negative percent change from Baseline reflects clinical improvement.

    Time frame: Baseline; 8 weeks

  3. Percent Change From Baseline to Week 8 in Non-HDL-C

    Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. LS mean percent change from Baseline to Week 8 was based on an ANCOVA model with effects of treatment and Baseline value as a covariate. Missing values at Week 8 were imputed using the LOCF procedure (only post-Baseline values were carried forward). A negative percent change from Baseline reflects clinical improvement.

    Time frame: Baseline; 8 weeks

  4. Percent Change From Baseline to Week 8 in Total Cholesterol

    Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. LS mean percent change from Baseline to Week 8 was based on an ANCOVA model with effects of treatment and Baseline value as a covariate. Missing values at Week 8 were imputed using the LOCF procedure (only post-Baseline values were carried forward). A negative percent change from Baseline reflects clinical improvement.

    Time frame: Baseline; 8 weeks

  5. Percent Change From Baseline to Week 8 in Triglycerides

    Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. LS mean percent change from Baseline to Week 8 was based on an ANCOVA model with effects of treatment and Baseline value as a covariate. Missing values at Week 8 were imputed using the LOCF procedure (only post-Baseline values were carried forward). A negative percent change from Baseline reflects clinical improvement.

    Time frame: Baseline; 8 weeks

  6. Percent Change From Baseline to Week 8 in Apolipoprotein B

    Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. LS mean percent change from Baseline to Week 8 was based on an ANCOVA model with effects of treatment and Baseline value as a covariate. Missing values at Week 8 were imputed using the LOCF procedure (only post-Baseline values were carried forward). A negative percent change from Baseline reflects clinical improvement.

    Time frame: Baseline; 8 weeks

  7. Percent Change From Baseline to Week 8 in Apolipoprotein AI

    Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. LS mean percent change from Baseline to Week 8 was based on an ANCOVA model with effects of treatment and Baseline value as a covariate. Missing values at Week 8 were imputed using the LOCF procedure (only post-Baseline values were carried forward). A negative percent change from Baseline reflects clinical improvement.

    Time frame: Baseline; 8 weeks

  8. Percent Change From Baseline to Week 8 in Lipoprotein (a)

    Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. LS mean percent change from Baseline to Week 8 was based on an ANCOVA model with effects of treatment and Baseline value as a covariate. Data are based on the participant's last post-Baseline value. Only those participants having a valid assessment at Baseline and each subsequent time point were included in the summaries at that time point. Lipoprotein (a) results indicated as \<3 in the laboratory data were set to 3 for purposes of analysis. A negative percent change from Baseline reflects clinical improvement.

    Time frame: Baseline; 8 weeks

  9. Percent Change From Baseline to Week 8 in High-Sensitivity C-Reactive Protein (hsCRP)

    Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. LS mean percent change from Baseline to Week 8 was based on an ANCOVA model with effects of treatment and Baseline value as a covariate. Data were based on the participant's last post-Baseline value. Only those participants having a valid assessment at Baseline and each subsequent time point were included in the summaries at that time point. hsCRP results indicated as \<0.2 in the laboratory data were set to 0.2 for purposes of analysis. A negative percent change from Baseline reflects clinical improvement.

    Time frame: Baseline; 8 weeks

  10. Percent Change From Baseline to Week 8 in Free Fatty Acids (FFA)

    Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. LS mean percent change from Baseline to Week 8 was based on an ANCOVA model with effects of treatment and Baseline value as a covariate. Data were based on the participant's last post-Baseline value.

    Time frame: Baseline; 8 weeks

  11. Number of Participants Achieving Their National Cholesterol Education Program Adult Treatment Panel III (NCEP ATPIII) LDL-C Goal (<100 Milligrams Per Deciliter [mg/dL]) After 8 Weeks of Treatment

    Participants were analyzed to evaluate the LDL-C target of \<100 mg/dL for high risk participants with cardiovascular diseases. Missing values at Week 8 were imputed using the LOCF procedure (only post-Baseline values were carried forward).

    Time frame: Baseline; up to 8 weeks

  12. Number or Participants With Treatment-emergent Adverse Events (TEAEs)

    TEAEs were defined as adverse events (AEs) that began or worsened in severity after the first dose of study medication, occurring up to 30 days after the last dose of study medication.

    Time frame: up to 8 weeks

  13. Number of Participants With Muscle-Related TEAEs

    TEAEs were defined as AEs that began or worsened in severity after the first dose of study medication, occurring up to 30 days after the last dose of study medication.

    Time frame: up to 8 weeks

07

Results

Posted Apr 4, 2022

Participant flow

Participant flow — Overall Study
MilestoneETC-1002Placebo
Started3719
Completed3115
Not completed64
Withdrew: Adverse event53
Withdrew: Withdrawal by subject01
Withdrew: Per investigator/sponsor/regulatory body10

Outcome measures

PrimaryPercent Change From Baseline to Week 8 in Calculated Low-Density Lipoprotein-Cholesterol (LDL-C)

Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. Least square (LS) mean percent change from Baseline to Week 8 was based on an analysis of covariance (ANCOVA) model with effects of treatment and Baseline value as a covariate. Missing LDL-C values at Week 8 were imputed using the last observation carried forward (LOCF) procedure (only post-Baseline values were carried forward). A negative percent change from Baseline reflects clinical improvement.

Time frame:
Baseline; 8 weeks
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline to Week 8 in Calculated Low-Density Lipoprotein-Cholesterol (LDL-C)
Percent ChangeETC-1002Placebo
Percent Change From Baseline to Week 8 in Calculated Low-Density Lipoprotein-Cholesterol (LDL-C)-32.0 ± 1.93-3.3 ± 2.69
Statistical analysis
  • ETC-1002 vs Placebo · ANCOVA · p = <0.0001 · Least squares mean difference: -28.7 · 95% CI -35.4 to -22.1The least squares mean difference was calculated as the value for the ETC-1002 60 mg arm minus the value for the placebo arm.
SecondaryPercent Change From Baseline to Weeks 2, 4, 6, and 8 in Calculated LDL-C

Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. LS mean percent change from Baseline was based on an ANCOVA model with effects of treatment and Baseline value as a covariate. A negative percent change from Baseline reflects clinical improvement.

Time frame:
Baseline; Weeks 2, 4, 6, and 8
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline to Weeks 2, 4, 6, and 8 in Calculated LDL-C
Percent ChangeETC-1002Placebo
Week 2-19.5 ± 1.83-1.4 ± 2.52
Week 4-31.0 ± 1.50-1.0 ± 2.12
Week 6-32.6 ± 2.28-3.8 ± 3.28
Week 8-32.6 ± 2.48-4.0 ± 3.51
Statistical analysis
  • ETC-1002 vs Placebo · ANCOVA · p = <0.0001 · Least squares mean difference: -18.0 · 95% CI -24.3 to -11.8Estimation from Week 2. The least squares mean difference was calculated as the value for the ETC-1002 60 mg arm minus the value for the placebo arm.
  • ETC-1002 vs Placebo · ANCOVA · p = <0.0001 · Least squares mean difference: -30.0 · 95% CI -35.2 to -24.7Estimation from Week 4. The least squares mean difference was calculated as the value for the ETC-1002 60 mg arm minus the value for the placebo arm.
  • ETC-1002 vs Placebo · ANCOVA · p = <0.0001 · Least squares mean difference: -28.8 · 95% CI -36.9 to -20.8Estimation from Week 6. The least squares mean difference was calculated as the value for the ETC-1002 60 mg arm minus the value for the placebo arm.
  • ETC-1002 vs Placebo · ANCOVA · p = <0.0001 · Least squares mean difference: -28.5 · 95% CI -37.2 to -19.8Estimation from Week 8. The least squares mean difference was calculated as the value for the ETC-1002 60 mg arm minus the value for the placebo arm.
SecondaryPercent Change From Baseline to Week 8 in High-Density Lipoprotein-Cholesterol (HDL-C)

Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. LS mean percent change from Baseline to Week 8 was based on an ANCOVA model with effects of treatment and Baseline value as a covariate. Missing values at Week 8 were imputed using the LOCF procedure (only post-Baseline values were carried forward). A negative percent change from Baseline reflects clinical improvement.

Time frame:
Baseline; 8 weeks
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline to Week 8 in High-Density Lipoprotein-Cholesterol (HDL-C)
Percent ChangeETC-1002Placebo
Percent Change From Baseline to Week 8 in High-Density Lipoprotein-Cholesterol (HDL-C)-8.2 ± 2.46-2.4 ± 3.51
Statistical analysis
  • ETC-1002 vs Placebo · ANCOVA · p = 0.1892 · Least squares mean difference: -5.8 · 95% CI -14.5 to 2.9The least squares mean difference was calculated as the value for the ETC-1002 60 mg arm minus the value for the placebo arm.
SecondaryPercent Change From Baseline to Week 8 in Non-HDL-C

Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. LS mean percent change from Baseline to Week 8 was based on an ANCOVA model with effects of treatment and Baseline value as a covariate. Missing values at Week 8 were imputed using the LOCF procedure (only post-Baseline values were carried forward). A negative percent change from Baseline reflects clinical improvement.

Time frame:
Baseline; 8 weeks
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline to Week 8 in Non-HDL-C
Percent ChangeETC-1002Placebo
Percent Change From Baseline to Week 8 in Non-HDL-C-25.4 ± 2.04-4.4 ± 2.88
Statistical analysis
  • ETC-1002 vs Placebo · ANCOVA · p = <0.0001 · Least squares mean difference: -20.9 · 95% CI -28.0 to -13.9The least squares mean difference was calculated as the value for the ETC-1002 60 mg arm minus the value for the placebo arm.
SecondaryPercent Change From Baseline to Week 8 in Total Cholesterol

Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. LS mean percent change from Baseline to Week 8 was based on an ANCOVA model with effects of treatment and Baseline value as a covariate. Missing values at Week 8 were imputed using the LOCF procedure (only post-Baseline values were carried forward). A negative percent change from Baseline reflects clinical improvement.

Time frame:
Baseline; 8 weeks
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline to Week 8 in Total Cholesterol
Percent ChangeETC-1002Placebo
Percent Change From Baseline to Week 8 in Total Cholesterol-22.2 ± 1.64-3.7 ± 2.32
Statistical analysis
  • ETC-1002 vs Placebo · ANCOVA · p = <0.0001 · Least squares mean difference: -18.4 · 95% CI -24.2 to -12.7The least squares mean difference was calculated as the value for the ETC-1002 60 mg arm minus the value for the placebo arm.
SecondaryPercent Change From Baseline to Week 8 in Triglycerides

Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. LS mean percent change from Baseline to Week 8 was based on an ANCOVA model with effects of treatment and Baseline value as a covariate. Missing values at Week 8 were imputed using the LOCF procedure (only post-Baseline values were carried forward). A negative percent change from Baseline reflects clinical improvement.

Time frame:
Baseline; 8 weeks
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline to Week 8 in Triglycerides
Percent ChangeETC-1002Placebo
Percent Change From Baseline to Week 8 in Triglycerides11.2 ± 6.34-7.4 ± 8.98
Statistical analysis
  • ETC-1002 vs Placebo · ANCOVA · p = =0.0962 · Least squares mean difference: 18.7 · 95% CI -3.5 to 40.8The least squares mean difference was calculated as the value for the ETC-1002 60 mg arm minus the value for the placebo arm.
SecondaryPercent Change From Baseline to Week 8 in Apolipoprotein B

Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. LS mean percent change from Baseline to Week 8 was based on an ANCOVA model with effects of treatment and Baseline value as a covariate. Missing values at Week 8 were imputed using the LOCF procedure (only post-Baseline values were carried forward). A negative percent change from Baseline reflects clinical improvement.

Time frame:
Baseline; 8 weeks
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline to Week 8 in Apolipoprotein B
Percent ChangeETC-1002Placebo
Percent Change From Baseline to Week 8 in Apolipoprotein B-19.7 ± 2.61-4.4 ± 3.77
Statistical analysis
  • ETC-1002 vs Placebo · ANCOVA · p = =0.0019 · Least squares mean difference: -15.3 · 95% CI -24.6 to -6.0The least squares mean difference was calculated as the value for the ETC-1002 60 mg arm minus the value for the placebo arm.
SecondaryPercent Change From Baseline to Week 8 in Apolipoprotein AI

Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. LS mean percent change from Baseline to Week 8 was based on an ANCOVA model with effects of treatment and Baseline value as a covariate. Missing values at Week 8 were imputed using the LOCF procedure (only post-Baseline values were carried forward). A negative percent change from Baseline reflects clinical improvement.

Time frame:
Baseline; 8 weeks
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline to Week 8 in Apolipoprotein AI
Percent ChangeETC-1002Placebo
Percent Change From Baseline to Week 8 in Apolipoprotein AI-4.2 ± 2.040.1 ± 2.98
Statistical analysis
  • ETC-1002 vs Placebo · ANCOVA · p = =0.2555 · Least squares mean difference: -4.2 · 95% CI -11.7 to 3.2The least squares mean difference was calculated as the value for the ETC-1002 60 mg arm minus the value for the placebo arm.
SecondaryPercent Change From Baseline to Week 8 in Lipoprotein (a)

Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. LS mean percent change from Baseline to Week 8 was based on an ANCOVA model with effects of treatment and Baseline value as a covariate. Data are based on the participant's last post-Baseline value. Only those participants having a valid assessment at Baseline and each subsequent time point were included in the summaries at that time point. Lipoprotein (a) results indicated as \<3 in the laboratory data were set to 3 for purposes of analysis. A negative percent change from Baseline reflects clinical improvement.

Time frame:
Baseline; 8 weeks
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline to Week 8 in Lipoprotein (a)
Percent ChangeETC-1002Placebo
Percent Change From Baseline to Week 8 in Lipoprotein (a)10.4 ± 5.78-1.2 ± 8.32
Statistical analysis
  • ETC-1002 vs Placebo · ANCOVA · p = 0.2563 · Least squares mean difference: 11.7 · 95% CI -8.8 to 32.1The least squares mean difference was calculated as the value for the ETC-1002 60 mg arm minus the value for the placebo arm.
SecondaryPercent Change From Baseline to Week 8 in High-Sensitivity C-Reactive Protein (hsCRP)

Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. LS mean percent change from Baseline to Week 8 was based on an ANCOVA model with effects of treatment and Baseline value as a covariate. Data were based on the participant's last post-Baseline value. Only those participants having a valid assessment at Baseline and each subsequent time point were included in the summaries at that time point. hsCRP results indicated as \<0.2 in the laboratory data were set to 0.2 for purposes of analysis. A negative percent change from Baseline reflects clinical improvement.

Time frame:
Baseline; 8 weeks
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline to Week 8 in High-Sensitivity C-Reactive Protein (hsCRP)
Percent ChangeETC-1002Placebo
Percent Change From Baseline to Week 8 in High-Sensitivity C-Reactive Protein (hsCRP)-22.6 ± 11.771.1 ± 16.74
Statistical analysis
  • ETC-1002 vs Placebo · ANCOVA · p = 0.2565 · Least squares mean difference: -23.7 · 95% CI -65.4 to 18.0The least squares mean difference was calculated as the value for the ETC-1002 60 mg arm minus the value for the placebo arm.
SecondaryPercent Change From Baseline to Week 8 in Free Fatty Acids (FFA)

Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. LS mean percent change from Baseline to Week 8 was based on an ANCOVA model with effects of treatment and Baseline value as a covariate. Data were based on the participant's last post-Baseline value.

Time frame:
Baseline; 8 weeks
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline to Week 8 in Free Fatty Acids (FFA)
Percent ChangeETC-1002Placebo
Percent Change From Baseline to Week 8 in Free Fatty Acids (FFA)14.3 ± 7.9910.4 ± 11.31
Statistical analysis
  • ETC-1002 vs Placebo · ANCOVA · p = 0.7760 · Least squares mean difference: 4.0 · 95% CI -24.1 to 32.0The least squares mean difference was calculated as the value for the ETC-1002 60 mg arm minus the value for the placebo arm.
SecondaryNumber of Participants Achieving Their National Cholesterol Education Program Adult Treatment Panel III (NCEP ATPIII) LDL-C Goal (<100 Milligrams Per Deciliter [mg/dL]) After 8 Weeks of Treatment

Participants were analyzed to evaluate the LDL-C target of \<100 mg/dL for high risk participants with cardiovascular diseases. Missing values at Week 8 were imputed using the LOCF procedure (only post-Baseline values were carried forward).

Time frame:
Baseline; up to 8 weeks
Reported as:
Count of participants · Participants
Number of Participants Achieving Their National Cholesterol Education Program Adult Treatment Panel III (NCEP ATPIII) LDL-C Goal (<100 Milligrams Per Deciliter [mg/dL]) After 8 Weeks of Treatment
ParticipantsETC-1002Placebo
Week 8: Achieved LDL-C Goal210
Week 8: Did Not Achieve LDL-C Goal1317
Statistical analysis
  • ETC-1002 vs Placebo · Fisher Exact · p = <0.0001 (Based on Fisher's exact test comparing the proportion of participants who achieved LDL-C goal at Week 8 (End of Study) in the ETC-1002 and placebo groups.) · Clopper-pearson methodology: 61.8 · 95% CI 45.4 to 78.1ETC-1002 minus placebo for the proportion of participants who achieved LDL-C goal at Week 8 (End of Study). The confidence interval was based on a normal approximation to the binomial distribution.
SecondaryNumber or Participants With Treatment-emergent Adverse Events (TEAEs)

TEAEs were defined as adverse events (AEs) that began or worsened in severity after the first dose of study medication, occurring up to 30 days after the last dose of study medication.

Time frame:
up to 8 weeks
Reported as:
Count of participants · Participants
Number or Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsETC-1002Placebo
Number or Participants With Treatment-emergent Adverse Events (TEAEs)2615
SecondaryNumber of Participants With Muscle-Related TEAEs

TEAEs were defined as AEs that began or worsened in severity after the first dose of study medication, occurring up to 30 days after the last dose of study medication.

Time frame:
up to 8 weeks
Reported as:
Count of participants · Participants
Number of Participants With Muscle-Related TEAEs
ParticipantsETC-1002Placebo
Number of Participants With Muscle-Related TEAEs127

Adverse events

Collected over up to 8 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ETC-10020/37 (0%)1/37 (2.7%)19/37 (51.4%)
Placebo0/19 (0%)0/19 (0%)15/19 (78.9%)
Most frequent serious events
Most frequent serious events
EventETC-1002Placebo
Thyroid CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/370/19
Most frequent other events
Showing 10 of 34
Most frequent other events
EventETC-1002Placebo
Upper Respiratory Tract InfectionInfections and infestations1/374/19
Muscle SpasmsMusculoskeletal and connective tissue disorders5/371/19
ArthralgiaMusculoskeletal and connective tissue disorders1/372/19
Muscular WeaknessMusculoskeletal and connective tissue disorders1/372/19
Musculoskeletal StiffnessMusculoskeletal and connective tissue disorders0/372/19
NauseaGastrointestinal disorders3/370/19
Urinary Tract InfectionInfections and infestations3/370/19
FatigueGeneral disorders2/371/19
NasopharyngitisInfections and infestations2/370/19
Pain In ExtremityMusculoskeletal and connective tissue disorders2/371/19

Baseline characteristics

Baseline data are reported for members of the Safety Population, comprised of all randomized participants who received at least 1 dose of study medication.

Age, Continuous
Age, Continuous(years)ETC-1002PlaceboTotal
Mean63.9 ± 5.4260.4 ± 7.8862.8 ± 6.51
Sex: Female, Male
Sex: Female, Male(Participants)ETC-1002PlaceboTotal
Female171128
Male20828
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ETC-1002PlaceboTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American202
White351954
More than one race000
Unknown or Not Reported000
Calculated Low-density Lipoprotein Cholesterol (LDL-C)
Calculated Low-density Lipoprotein Cholesterol (LDL-C)(milligrams per deciliter (mg/dL))ETC-1002PlaceboTotal
Mean175.7 ± 36.52184.8 ± 32.53178.9 ± 35.16
08

Study locations

5 sites
  • Hartford, Connecticut 06102, United States
  • Indianapolis, Indiana 46260, United States
  • Raleigh, North Carolina 27609, United States
  • Wilmington, North Carolina 28401, United States
  • Knoxville, Tennessee 37912, United States
09

References and documents

Publications

  • Thompson PD, Rubino J, Janik MJ, MacDougall DE, McBride SJ, Margulies JR, Newton RS. Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance. J Clin Lipidol. 2015 May-Jun;9(3):295-304. doi: 10.1016/j.jacl.2015.03.003. Epub 2015 Mar 19. PubMed 26073387 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2012 to primary completion in May 2013, 6 months.

Results were first posted in Apr 2022, 8 years 11 months after primary completion. A results delay was requested in Aug 2015.

Of 41 industry-sponsored phase 2 interventional studies under Hypercholesterolemia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 14. This study's 6 months is below that.

Counting every sponsor, half of 48 studies reached it within 10 months; a quarter within 7 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2012
First posted
Dec 18, 2012
StartActual
Oct 4, 2012
Primary completionActual
May 1, 2013
CompletionActual
May 1, 2013
Results delay requested
Aug 13, 2015
Results first posted
Apr 4, 2022
Last update
Apr 4, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01751984
Responsible party
Sponsor
First posted
Dec 18, 2012
Start date
Oct 4, 2012
Primary completion
May 1, 2013
Completion
May 1, 2013
Results posted
Apr 4, 2022
Last update
Apr 4, 2022

Study contacts

Medical Director
study director · Esperion Therapeutics, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bempedoic acid

Start the discussion